Intrinsic Value

Returns vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock in ASM list and too much promoter holding pledged

Red Flags Found

ERIS Lifesciences Ltd, RPSG Ventures Ltd, Panacea Biotec Ltd and Godrej Properties Ltd are among the other losers in the BSE’s ‘A’ group today, 17 November 2021.

Lemon Tree Hotels Ltd leads losers in ‘A’ group

1) Biocon: unit Biocon Biologics and U.S.-based Viatris Inc. roll out interchangeable biosimilars injection Semglee and Insulin Glargine injection, used to control high blood sugar and diabetes, in the U.S. market.

2) UGRO Capital says total disbursements stood at Rs 320  cr in October, up 11% on the month, while collection efficiency remained stable.  

3) Linde India company's JV firm accepts JSW Steel’s offer for the purchase of the 855 tonnes per day Air Separation Unit and other related assets. Linde receives Rs 500 cr as its share from the transaction. 

4) Panacea Biotec Pharma, a 100% subsidiary of Sputnik V Covid jab manufacturer Panacea Biotec, defaulted on payment of ₹114.67 crores including an interest component due on September 30. The company says "There is no default on the above referred NCD, as the repayment date has been extended as per mutual agreement with the lenders.": ET reports 

5) UBS ON NYKAA 
Initiate with BUY, Target at `2750/share 
Long runway for profitable growth 

6) TV Today  
Abakkus Asset Manager bought 8lk shares @ 345 x
Subscribe To ET Now For Latest Updates On Stocks, Business, Trading | ► https://goo.gl/SEjvK3

Subscribe Now To Our Network Channels :-
Times Now  : http://goo.gl/U9ibPb
The NewsHour Debate : http://goo.gl/LfNgFF

To Stay Updated Download the Times Now App :-
Android Google Play :  https://goo.gl/zJhWjC
Apple App Store :  https://goo.gl/d7QBQZ

Social Media Links :-
Twitter - http://goo.gl/hA0vDt
Facebook - http://goo.gl/5Lr4mC
G+ - http://goo.gl/hYxrmj
Website - www.etnownews.com

UGRO Capital up by 11% this month; Panacea Biotec Pharma default on payment | Stocks to Watch

Here is a quick update on the stocks which are in news this morning namely, Biocon, Panacea Biotec, Eicher Motors, Poonawalla Finance and Linde India. Listen in here to the latest news updates on these stocks.

#CNBCTV18 #BusinessNews #ShareMarketToday #Nifty #Sensex #StocksInNews

CNBC-TV18 is India's No.1 Business medium and the undisputed leader in business news. The channel's benchmark coverage extends from corporate news, financial markets coverage, expert perspective on investing and management to industry verticals and beyond. CNBC-TV18 has been constantly innovating with new genres of programming that helps make business more relevant to different constituencies across India. India's most able business audience consumes CNBC-TV18 for their information & investing needs. This audience is highly diversified at one level comprising of key groups such as business leaders, professionals, retail investors, brokers and traders, intermediaries, self-employed professionals, High Net Worth individuals, students and even homemakers but shares a distinct commonality in terms of their spirit of enterprise.

For latest news and updates visit our Website: https://bit.ly/2YbpXBM
Subscribe to our Channel: https://www.youtube.com/user/CNBCTV18
Like us on Facebook: https://www.facebook.com/cnbctv18india/
Follow us on Twitter: https://twitter.com/CNBCTV18News

Stocks In News: Biocon, Panacea Biotec, Eicher Motors & More | Bazaar Morning Call | CNBC-TV18

Panacea Biotec Pharma, a 100% subsidiary of Sputnik V Covid jab manufacturer Panacea Biotec, defaulted on payment of ₹114.67 crore including an interest component due on September 30.

Panacea arm defaults; lenders may extend repayment date

Suven Life Sciences Ltd, Rail Vikas Nigam Ltd, Panacea Biotec Ltd and Apollo Pipes Ltd are among the other losers in the BSE’s ‘A’ group today, 25 October 2021.

Indian Railway Catering & Tourism Corporation Ltd leads losers in ‘A’ group

#CNBCAwaazLive #AajKaTajaKhabar #BusinessNewsLive #StockMarketLive #ShareMarketLive

Panacea Biotec Stock में आज खरीदारी का मौका बन रहा है। इस Stock में Breakout दिख रहा है। ऐसे में इस Stock में खरीदारी को लेकर Ashish Chaturmohta संग बनाएं विशेष रणनीति, देखें वीडियो

Share Market से जुड़ी हर छोटी या बड़ी खबर, चाहे हो Nifty में आए नए हाई या फिर, हो आपके के लिए स्टॉक्स पर राय, बिजनेस न्यूज हो या पॉलिटिकल न्यूज, कोरोनावायरस की न्यूज हो या फिर इलेक्शन, देखें CNBC Awaaz और रहे हर खबर से updated.


CNBC Awaaz is India’s number one business channel and an undisputed leader in business news and information for the last ten years. Our channel aims to educate, inform and inspire consumers to go beyond limitations, with practical tips on personal finance, investing, technology, consumer goods and capital markets. Policymakers and business owners alike have grown to trust CNBC Awaaz as the most reliable source with its eye on India’s business climate. Our programming gives consumers a platform to make decisions with confidence.

Subscribe to the CNBC Awaaz YouTube channel here: https://tinyurl.com/y5rsvesk

Follow CNBC Awaaz on Twitter: https://twitter.com/CNBC_Awaaz
Like us on our CNBC Awaaz Facebook page: https://www.facebook.com/cnbcawaaz
Website: https://bit.ly/3230WJW

Panacea Biotec Stock में दिख रहा जबरदस्त Action, Stock में दिख रहा शानदार Breakout | CNBC Awaaz

The second jab of the Sputnik vaccine comprises human adenovirus serotype 5. Sputnik V uses two different vectors for the two shots of the Covid-19 vaccine.

Covid-19: Panacea Biotec starts supplying second component of Sputnik V vaccine

To be distributed in India through Dr Reddy’s Laboratories

Panacea Biotec supplies second component of Sputnik vaccine

Hospital industry sources claim they want assurance on shelf life of imported vaccines

DRL steps up Sputnik V supplies with second dose from Panacea Biotec

The batch will be distributed in India through Dr Reddy’s Laboratories. To date, Sputnik V has been authorised in 70 countries

Panacea Biotec supplies first shipment of Sputnik V component II developed in India

The first batch will be distributed in India through a partner of RDIF and Panacea Biotec – Dr Reddy’s Laboratories.

Panacea Biotech and RDIF supply first shipment of the second component of Sputnik V vaccine in India; Stock hits 10% upper circuit

Panacea Biotec Limited is a health management company. The Company's principal business activity is the manufacture of allopathic pharmaceuticals preparations.

Panacea Biotec Ltd

Panacea Biotec Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Lemon Tree Hotels Ltd leads losers in ‘A’ group

News Video

UGRO Capital up by 11% this month; Panacea Biotec Pharma default on payment | Stocks to Watch

News Video

Stocks In News: Biocon, Panacea Biotec, Eicher Motors & More | Bazaar Morning Call | CNBC-TV18

Panacea arm defaults; lenders may extend repayment date

Indian Railway Catering & Tourism Corporation Ltd leads losers in ‘A’ group

News Video

Panacea Biotec Stock में दिख रहा जबरदस्त Action, Stock में दिख रहा शानदार Breakout | CNBC Awaaz

Covid-19: Panacea Biotec starts supplying second component of Sputnik V vaccine

Panacea Biotec Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Lemon Tree Hotels Ltd leads losers in ‘A’ group

News Video

UGRO Capital up by 11% this month; Panacea Biotec Pharma default on payment | Stocks to Watch

News Video

Stocks In News: Biocon, Panacea Biotec, Eicher Motors & More | Bazaar Morning Call | CNBC-TV18

Panacea arm defaults; lenders may extend repayment date

Indian Railway Catering & Tourism Corporation Ltd leads losers in ‘A’ group

News Video

Panacea Biotec Stock में दिख रहा जबरदस्त Action, Stock में दिख रहा शानदार Breakout | CNBC Awaaz

Covid-19: Panacea Biotec starts supplying second component of Sputnik V vaccine

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock